Outsourcing-Pharma's Liza Laws recently interviewed uMotif Chief Marketing Officer #CMO Elaine Maynard for a new Women in Science profile. Elaine shares insights into her career trajectory and how her life-long interest in the power of clinical trials inspired her 2-decade journey in the #lifesciences industry and commitment to placing #patientsfirst—a philosophy that’s central to her role at uMotif. https://lnkd.in/e3cC_Rh8 #womeninscience #clinicaltrials
uMotif
Software Development
London, United Kingdom 12,145 followers
Engaged Patients. Better Trials.
About us
uMotif's mission is to put patients at the center of clinical research. Designed with patients for patients, the uMotif patient-first eClinical platform powers site-based to fully decentralized clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture large volumes of eCOA/ePRO, symptom, and wearable device data. www.umotif.com
- Website
-
http://www.uMotif.com
External link for uMotif
- Industry
- Software Development
- Company size
- 51-200 employees
- Headquarters
- London, United Kingdom
- Type
- Privately Held
- Founded
- 2012
- Specialties
- ePRO, digital health, eCOA, clinical trials, patient engagement, real-world studies, late-phase, post-marketing, and non-interventional
Locations
-
Primary
Get directions
London, United Kingdom, GB
-
Get directions
Boston, US
Employees at uMotif
Updates
-
Today is Glioblastoma Awareness Day. uMotif is forever grateful for the opportunity to work with Jessica Morris, founder of OurBrainBank for Glioblastoma. Jessica let us into her healthcare journey and helped push us to develop truly patient-centric software. https://lnkd.in/d5p6BNRg #GBMDay #OurBrainBank #GBM #Glioblastoma
-
-
The uMotif team continues to grow. We’re excited to welcome Michael McGloughlin, our new Senior Director, Business Development for EMEA. Michael has more than two decades of experience in pharmaceutical and clinical trial technology business development with industry-leading organizations. We look forward to Michael’s contributions as we continue to bring our modern, patient-centric eCOA/ePRO platform to sponsors and CROs.
-
-
Looking to dive deeper into #ePRO best practices? Watch this on-demand Masterclass featuring uMotif’s Ben James as part of a panel of industry leaders. Learn about proven strategies for #electronicmigration and implementation of ePRO measures based on a recent Value in Health article, to which the panelists contributed. https://lnkd.in/ebb9ESSM Florence Mowlem, PhD Melissa Newara #clinicaltrials
-
-
#DIA celebrates its 60th anniversary this week, and uMotif will be there. Charting New Horizons, the theme for the milestone event, is a philosophy that uMotif embraces with our modern #eCOA/#ePRO solutions that place the patient at the center of the #clinicaltrial journey. Our team, including Steve Rosenberg, Don Butler, and Tim McManus, look forward to seeing you in San Diego. #DIA2024
-
-
OutsourcingPharma spotlights uMotif and how our modern #eCOA/#ePRO solutions are empowering patients and advancing #clinicaltrials, including #CNS research. Read the full article which includes perspective from uMotif CEO Steve Rosenberg. https://lnkd.in/ecpN56ay
-
-
Be sure to catch Bruce Hellman today at #OCTUK #OCTIreland, where he presents strategies and technologies that put patients at the center of their clinical trial journey to drive greater engagement, #ePRO compliance, and more efficient #clinicaltrials. #patientsfirst #patientcentricity
-
-
uMotif continues the #OCT circuit this week with #OCTUK #OCTIreland. Visit us at Booth 20 where Bruce Hellman, Ben James and Michael McGloughlin are ready to share the latest in #eCOA/#ePRO innovation for #clinicaltrials. See you there!
-